In vivo hematopoietic stem cell modification by mRNA delivery

Laura Breda(Children's Hospital of Philadelphia), Tyler E. Papp(University of Pennsylvania), Michael Triebwasser(Children's Hospital of Philadelphia), Amir Yadegari(University of Pennsylvania), Megan T. Fedorky(Children's Hospital of Philadelphia), Naoto Tanaka(Children's Hospital of Philadelphia), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Giulia Pavani(Children's Hospital of Philadelphia), Yongping Wang(Children's Hospital of Philadelphia), Stephan A. Grupp(Children's Hospital of Philadelphia), Stella T. Chou(Children's Hospital of Philadelphia), Houping Ni(University of Pennsylvania), Barbara L. Mui(Acuitas Therapeutics (Canada)), Ying K. Tam(Acuitas Therapeutics (Canada)), Drew Weissman(University of Pennsylvania), Stefano Rivella(Children's Hospital of Philadelphia), Hamideh Parhiz(University of Pennsylvania)
Science
July 27, 2023
10.1126/science.ade6967
Cited by 297Open Access
Full Text

Abstract

Hematopoietic stem cells (HSCs) are the source of all blood cells over an individual's lifetime. Diseased HSCs can be replaced with gene-engineered or healthy HSCs through HSC transplantation (HSCT). However, current protocols carry major side effects and have limited access. We developed CD117/LNP-messenger RNA (mRNA), a lipid nanoparticle (LNP) that encapsulates mRNA and is targeted to the stem cell factor receptor (CD117) on HSCs. Delivery of the anti-human CD117/LNP-based editing system yielded near-complete correction of hematopoietic sickle cells. Furthermore, in vivo delivery of pro-apoptotic PUMA (p53 up-regulated modulator of apoptosis) mRNA with CD117/LNP affected HSC function and permitted nongenotoxic conditioning for HSCT. The ability to target HSCs in vivo offers a nongenotoxic conditioning regimen for HSCT, and this platform could be the basis of in vivo genome editing to cure genetic disorders, which would abrogate the need for HSCT.

Related Papers

A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Linda Madisen, Theresa A. Zwingman, Susan M. Sunkin et al.|Nature Neuroscience|2009|7.3k
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Katalin Karikó, Michael Buckstein, Houping Ni et al.|Immunity|2005|2.6k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc, William Querbes, Soma De et al.|Molecular Therapy|2010|1.2k
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Katalin Karikó, Hiromi Muramatsu, János Ludwig et al.|Nucleic Acids Research|2011|874
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier, Muthusamy Jayaraman, Shigeo Matsuda et al.|Molecular Therapy|2013|615